Latest Ratios: P/E Ratio 53.6x · EV/EBITDA 14.6x · ROE 4.5%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $57.6B | $45.1B | $39.6B | $34.1B | $42.6B | $35.1B | $29.1B | $22.2B | — | — |
| Enterprise Value | $55.7B | $43.2B | $39.2B | $34.0B | $40.7B | $31.7B | $26.7B | $20.5B | — | — |
| P/E Ratio → | 53.63 | 41.89 | 43.82 | 46.52 | 37.20 | 19.95 | 42.55 | — | — | — |
| P/S Ratio | 3.31 | 2.59 | 2.34 | 1.98 | 2.44 | 2.24 | 2.05 | 1.60 | — | — |
| P/B Ratio | 2.37 | 1.85 | 1.65 | 1.35 | 1.67 | 1.37 | 1.16 | 0.90 | — | — |
| P/FCF | 20.46 | 16.03 | 25.61 | 29.06 | 159.50 | 16.28 | 18.30 | — | — | — |
| P/OCF | 16.91 | 13.25 | 18.48 | 19.28 | 48.84 | 12.86 | 14.09 | 20.71 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.48 | 2.32 | 1.97 | 2.33 | 2.03 | 1.88 | 1.48 | — | — |
| EV / EBITDA | 14.56 | 11.30 | 11.81 | 10.23 | 12.92 | 12.39 | 13.20 | 9.40 | — | — |
| EV / EBIT | 21.25 | 23.12 | 26.02 | 25.61 | 27.04 | 13.35 | 37.04 | — | — | — |
| EV / FCF | — | 15.34 | 25.35 | 28.93 | 152.44 | 14.73 | 16.78 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 43.6% | 43.6% | 43.6% | 42.4% | 40.2% | 41.1% | 40.2% | 38.1% | 30.4% | 41.0% |
| Operating Margin | 15.1% | 15.1% | 12.4% | 12.2% | 11.0% | 8.4% | 5.9% | 4.2% | -3.1% | 1.3% |
| Net Profit Margin | 6.3% | 6.3% | 5.4% | 4.3% | 6.6% | 11.2% | 4.8% | -6.9% | -35.5% | 17.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.5% | 4.5% | 3.7% | 2.9% | 4.5% | 6.9% | 2.7% | -1.9% | -6.7% | 3.4% |
| ROA | 2.6% | 2.6% | 2.2% | 1.7% | 2.7% | 4.1% | 1.6% | -1.3% | -4.6% | 2.2% |
| ROIC | 8.5% | 8.5% | 6.4% | 6.5% | 6.3% | 4.4% | 2.8% | 0.8% | -0.4% | 0.2% |
| ROCE | 8.6% | 8.6% | 6.7% | 6.5% | 6.0% | 3.9% | 2.5% | 0.9% | -0.5% | 0.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.11 | 0.10 | 0.05 | 0.04 | 0.04 | 0.01 | 0.11 | 0.17 |
| Debt / EBITDA | 0.68 | 0.68 | 0.81 | 0.75 | 0.41 | 0.44 | 0.55 | 0.06 | 3.39 | 28.54 |
| Net Debt / Equity | — | -0.08 | -0.02 | -0.01 | -0.07 | -0.13 | -0.10 | -0.07 | 0.08 | 0.07 |
| Net Debt / EBITDA | -0.51 | -0.51 | -0.12 | -0.05 | -0.60 | -1.30 | -1.20 | -0.75 | 2.42 | 11.49 |
| Debt / FCF | — | -0.69 | -0.26 | -0.13 | -7.06 | -1.55 | -1.52 | — | — | — |
| Interest Coverage | 10.38 | 10.38 | 6.47 | 5.69 | 19.05 | 79.20 | 16.00 | -1.32 | -19.20 | -4.05 |
Net cash position: cash ($4.5B) exceeds total debt ($2.6B)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.43 | 1.43 | 1.45 | 1.56 | 1.56 | 1.63 | 1.73 | 1.64 | 1.73 | 1.90 |
| Quick Ratio | 0.96 | 0.96 | 0.93 | 0.90 | 0.93 | 1.08 | 1.16 | 1.03 | 1.33 | 1.19 |
| Cash Ratio | 0.37 | 0.37 | 0.31 | 0.26 | 0.31 | 0.48 | 0.44 | 0.21 | 0.17 | 0.72 |
| Asset Turnover | — | 0.41 | 0.41 | 0.40 | 0.41 | 0.37 | 0.33 | 0.33 | 0.13 | 0.13 |
| Inventory Turnover | 1.73 | 1.73 | 1.75 | 1.44 | 1.53 | 1.78 | 1.74 | 1.70 | 1.87 | 0.97 |
| Days Sales Outstanding | — | 133.64 | 122.53 | 116.28 | 119.21 | 112.17 | 126.47 | 145.73 | 134.38 | 134.29 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.8% | 1.1% | 1.2% | 1.3% | 1.0% | 1.1% | 1.3% | 2.3% | — | — |
| Payout Ratio | 43.4% | 43.4% | 50.5% | 59.7% | 36.4% | 22.6% | 57.0% | — | — | 72.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.9% | 2.4% | 2.3% | 2.1% | 2.7% | 5.0% | 2.4% | — | — | — |
| FCF Yield | 4.9% | 6.2% | 3.9% | 3.4% | 0.6% | 6.1% | 5.5% | — | — | — |
| Buyback Yield | 1.9% | 2.4% | 2.5% | 2.2% | 2.3% | 2.7% | 0.9% | 0.1% | — | — |
| Total Shareholder Yield | 2.7% | 3.4% | 3.7% | 3.5% | 3.3% | 3.8% | 2.3% | 2.4% | — | — |
| Shares Outstanding | — | $673M | $696M | $712M | $725M | $742M | $751M | $750M | $749M | $749M |
Seasonal Commodity Price Sensitivity
According to current market data, Corteva trades at a trailing P/E of 51.62, which appears to command a significant premium relative to broader agricultural peers, suggesting that investors are pricing in the long-term durability of its proprietary seed genetics and biotechnology pipeline over cyclical commodity-linked earnings.
The forward P/E of 22.07 indicates that the market anticipates a substantial earnings recovery, likely driven by the continued adoption of the Enlist E3 platform. However, the PEG ratio of 4.32 suggests that this valuation may be stretched if the company fails to deliver consistent, high-single-digit earnings growth in the coming fiscal years.
Based on reported financial figures, ROIC has fluctuated significantly, ranging from a negative 1.2% in 2024Q3 to a peak of 5.1% in 2025Q2, illustrating that the company's ability to compound capital is heavily tethered to the timing of seasonal seed sales and chemical distribution cycles.
The volatility in ROIC suggests that the company's underlying asset base is not yet generating consistent returns above its cost of capital. Investors should monitor whether the transition toward internally developed traits can structurally improve these returns by reducing the reliance on high-cost, third-party licensing arrangements.
As indicated by the 2025Q4 data, the cash conversion cycle reached 209 days, reflecting the extreme working capital intensity required to manage global seed production and distribution, which remains a primary structural hurdle for maintaining consistent operational efficiency throughout the fiscal year.
The high DSO and DIO figures suggest that Corteva is effectively acting as a financier for its customer base during the planting season. This reliance on extended credit terms warrants close monitoring, as any deterioration in US farm income could lead to increased collection risks and liquidity pressure.
Based on recent balance sheet disclosures, Corteva maintains a robust financial position with a debt-to-equity ratio of 0.11%, which appears exceptionally conservative compared to peers and provides the company with significant flexibility to navigate cyclical downturns in the agricultural input sector without compromising its core operations.
The low leverage profile is a key differentiator that allows the company to sustain its dividend and share repurchase programs despite the inherent volatility in its cash flows. This balance sheet strength may be a critical asset if management chooses to pursue further M&A in the biologicals space.
The market frequently misapplies standard P/E multiples to Corteva by treating it as a cyclical chemical manufacturer, which obscures the underlying value of its proprietary germplasm library and the recurring, royalty-like nature of its high-margin seed trait business model.
Analysts should instead focus on EV/EBITDA or adjusted free cash flow metrics that account for the company's R&D-heavy cost structure and seasonal working capital swings. Relying on simple P/E ratios fails to capture the long-term competitive advantage provided by the company's integrated seed and chemistry platform.
Includes 30+ ratios · 9 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CTVA stock.
Corteva, Inc.'s current P/E ratio is 53.6x. The historical average is 38.7x. This places it at the 100th percentile of its historical range.
Corteva, Inc.'s current EV/EBITDA is 14.6x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 11.6x.
Corteva, Inc.'s return on equity (ROE) is 4.5%. The historical average is 2.2%.
Based on historical data, Corteva, Inc. is trading at a P/E of 53.6x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Corteva, Inc.'s current dividend yield is 0.82% with a payout ratio of 43.4%.
Corteva, Inc. has 43.6% gross margin and 15.1% operating margin. Operating margin between 10-20% is typical for established companies.
Corteva, Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.